| Literature DB >> 26463904 |
Hendrike Dahmke1, Hugo Kupferschmidt1,2, Gerd A Kullak-Ublick1, Stefan Weiler1.
Abstract
Nalmefene (Selincro®) is a selective opioid receptor antagonist, licensed in April 2014 in Switzerland for the reduction of alcohol consumption in adults with a high drinking risk level. 200 reports of adverse drug reactions of nalmefene have been documented worldwide in the WHO global pharmacovigilance database between 7th March 1997 to 1st March 2015. In 21 cases (10,5%) nalmefene and an opioid were administered concomitantly, causing withdrawal symptoms. Until now, the regional pharmacovigilance center in Zurich received four cases of nalmefene combined with opioids. This combination should be avoided.Entities:
Keywords: Alkoholabhängigkeit; Arzneimittelinteraktion; Entzugssymptome; Entzugssyndrom; Opioidrezeptoren; alcohol dependence; drug-drug interaction; dépendance à l’alcool; interactions médicamenteuses; opioid receptors; récepteurs opioïdes; symptômes de sevrage; syndrome de sevrage; withdrawal symptoms; withdrawal syndrome
Mesh：
Substances：
Year: 2015 PMID： 26463904 DOI： 10.1024/1661-8157/a002160
Source DB: PubMed Journal: Praxis (Bern 1994) ISSN： 1661-8157